Compare Pfizer Inc (PFE) vs Zillow Group Inc Class A (ZG) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

Zillow Group (ZG) trades at $31.80, down 5.67% over 24 hours, amid a bearish technical signal and negative news flow. The company reported revenue of $2.58B in 2025 with a net income of $23M, marking a return to profitability after losses in prior years. However, a high P/E ratio of 131.36 suggests premium valuation, while recent earnings showed a mix of beats and misses. Multiple law firms have announced securities class action investigations related to an alleged anticompetitive agreement, contributing to investor uncertainty.

The outlook is clouded by legal risks and rich valuation, though analyst consensus remains positive with a $57.80 price target. Upside potential hinges on sustained revenue growth and margin expansion, but downside risks include litigation outcomes and competitive pressures. Investors should weigh the strong analyst buy rating against fundamental headwinds.